Cooperative Agreement U54CA302452
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$2.5M
Federal Agency
National Cancer Institute
Federal Grant Program
93.397
Assistance Type
Cooperative Agreement
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $714,062 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the biological mechanisms contributing to racial disparities in head and neck cancer outcomes, particularly among Black patients. The key objectives are to: 1) Develop a prognostic model using gene expression signatures to predict disease progression in early-stage oral squamous cell...
This National Cancer Institute (NCI) Project Grant award under CFDA 93.396 - Cancer Biology Research provides $552,874 in funding to The Regents of the University of California, San Francisco (UCSF) from August 1, 2024 to July 31, 2029. The project aims to dissect the cellular and molecular pathways by which the A20 protein regulates anti-tumor immunity. Specifically, the research will focus on understanding how A20, a potent regulator of immune homeostasis, restrains both acute and anamnestic...
This Project Grant award from the National Cancer Institute (NCI), under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), provides $369,354.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the tumor immune microenvironment and response to immunotherapy among different racial and ethnic populations with breast cancer. The key objectives of this research project are: 1) to determine how frequently women of different...
The Regents of the University of California, San Francisco (UCSF) has been awarded a $1,453,500 Project Grant under the Trans-NIH Research Support (CFDA 93.310) program, administered by the National Institutes of Health (NIH). The grant, titled "Simulating Ancestrally Unbiased Tumor Evolution to Interrogate Drug Resistance Among Cancer Patients of Distinct Ancestries," aims to develop an immunocompetent organoid-based tumor graft system, called BRUTE (Barcoded Unsupervised Tumor...
The National Cancer Institute (NCI) awarded a 5-year, $3,537,456 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The Regents of the University of California, San Francisco (UCSF) to conduct research on optimizing subtype-specific breast cancer screening and prevention. The project aims to develop improved risk assessment models that can predict the specific type of breast cancer a woman is likely to develop, in order to tailor screening and prevention...
The Department of the Army Medical Command awarded a $5.3 million cooperative agreement to the Regents of the University of California, San Francisco for the period of August 1, 2022 through July 31, 2026. The award will support the University's efforts to prevent lethal metastatic breast cancer through the identification and eradication of clinically relevant disseminated tumor cells. This cooperative agreement was awarded under the Military Medical Research and Development program (CFDA...
The National Cancer Institute (NCI) awarded a $4,408,316 Project Grant under the Cancer Centers Support Grants (CFDA 93.397) program to the University of California, San Francisco (UCSF) to support its Specialized Programs of Research Excellence (SPORE) in Prostate Cancer. The overarching goal of this 5-year grant, effective September 2, 2024, is to reduce the morbidity and mortality associated with prostate cancer by leveraging a deep understanding of the disease to translate biological...
The National Cancer Institute (NCI) awarded a $791,820 Cooperative Agreement under CFDA 93.396 - Cancer Biology Research to the University of California, San Diego (UCSD) to advance the METASPACE open-source software platform for spatial metabolomics in cancer research. The project aims to enhance METASPACE's utility and accelerate the adoption of spatial metabolomics, which provides unprecedented insights into the tumor microenvironment, cell-cell heterogeneity, and metabolic reprogramming in...
This federal Project Grant award of $334,233, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, will support a comprehensive research study examining disparities in novel cancer therapies, the joint effects of cancer treatment and comorbidities, and multi-level contributors to cancer survival outcomes. The University of South Carolina, the prime awardee, will conduct innovative data linkages between the state cancer registry,...
The National Cancer Institute (NCI) awarded a $1,019,013 Cooperative Agreement under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) to the Regents of the University of California, San Francisco (UCSF) to develop a Pre-Cancer Atlas of Skin Cancer. The overarching goal is to study the early stages of skin cancer development, including melanoma and cutaneous squamous cell carcinoma, and the role of the immune system in this transition from pre-cancer to cancer. The...